CN103442694B - 治疗感染性疾病的肺部给药的抗感染分子微粒制剂 - Google Patents

治疗感染性疾病的肺部给药的抗感染分子微粒制剂 Download PDF

Info

Publication number
CN103442694B
CN103442694B CN201180043763.9A CN201180043763A CN103442694B CN 103442694 B CN103442694 B CN 103442694B CN 201180043763 A CN201180043763 A CN 201180043763A CN 103442694 B CN103442694 B CN 103442694B
Authority
CN
China
Prior art keywords
formula
compound
formulation
microparticle
dppc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180043763.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN103442694A (zh
Inventor
格坦加利·常德拉舍克哈·芝莫特
吉利什·巴垂那特·马哈詹
阿拉瓦丹·瓦苏德万
西瓦拉马克克里斯南·哈里哈兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Piramal Enterprises Ltd
Original Assignee
Piramal Enterprises Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Enterprises Ltd filed Critical Piramal Enterprises Ltd
Publication of CN103442694A publication Critical patent/CN103442694A/zh
Application granted granted Critical
Publication of CN103442694B publication Critical patent/CN103442694B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201180043763.9A 2010-08-05 2011-08-04 治疗感染性疾病的肺部给药的抗感染分子微粒制剂 Expired - Fee Related CN103442694B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US37091610P 2010-08-05 2010-08-05
US61/370,916 2010-08-05
US61/370916 2010-08-05
PCT/IB2011/053470 WO2012017405A1 (en) 2010-08-05 2011-08-04 Microparticle formulation for pulmonary drug delivery of anti-infective molecule for treatment of infectious diseases

Publications (2)

Publication Number Publication Date
CN103442694A CN103442694A (zh) 2013-12-11
CN103442694B true CN103442694B (zh) 2015-09-09

Family

ID=44653372

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180043763.9A Expired - Fee Related CN103442694B (zh) 2010-08-05 2011-08-04 治疗感染性疾病的肺部给药的抗感染分子微粒制剂

Country Status (14)

Country Link
US (1) US8697653B2 (cg-RX-API-DMAC7.html)
EP (1) EP2600842A1 (cg-RX-API-DMAC7.html)
JP (1) JP2013532722A (cg-RX-API-DMAC7.html)
KR (1) KR20130109106A (cg-RX-API-DMAC7.html)
CN (1) CN103442694B (cg-RX-API-DMAC7.html)
AU (1) AU2011287205A1 (cg-RX-API-DMAC7.html)
BR (1) BR112013002641A2 (cg-RX-API-DMAC7.html)
CA (1) CA2807357A1 (cg-RX-API-DMAC7.html)
IN (1) IN2013MN00329A (cg-RX-API-DMAC7.html)
MX (1) MX2013001325A (cg-RX-API-DMAC7.html)
RU (1) RU2013109384A (cg-RX-API-DMAC7.html)
TW (1) TW201208716A (cg-RX-API-DMAC7.html)
WO (1) WO2012017405A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201301662B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015107482A1 (en) * 2014-01-17 2015-07-23 Piramal Enterprises Limited Pharmaceutical combination for treatment of tuberculosis
US10335374B2 (en) 2014-12-04 2019-07-02 University System of Georgia, Valdosta State University Tablet composition for anti-tuberculosis antibiotics
CN109827875A (zh) * 2019-04-10 2019-05-31 上海市食品药品检验所 一种用于测定吸入制剂溶出度的装置和方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4877561A (en) * 1986-04-02 1989-10-31 Takeda Chemical Industries, Ltd. Method of producing liposome
WO2001054693A1 (en) * 2000-01-31 2001-08-02 Eisai Co., Ltd. Use of thiostrepton as an anti-mycobacterial agent
WO2008127746A1 (en) * 2007-01-10 2008-10-23 Board Of Regents The University Of Texas System Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8601457D0 (sv) * 1986-04-01 1986-04-01 Draco Ab Compositions of liposomes and b?712-receptor active substances for inhalation
TW497974B (en) * 1996-07-03 2002-08-11 Res Dev Foundation High dose liposomal aerosol formulations
WO2000027359A1 (en) * 1998-11-12 2000-05-18 Pilkiewicz Frank G An inhalation system
EP1490027A4 (en) * 2002-03-05 2010-11-10 Transave Inc METHODS OF TRAPPING BIOACTIVE AGENT IN A LIPOSOME OR LIPID COMPLEX
EP2473516A1 (en) 2009-09-02 2012-07-11 Piramal Life Sciences Limited Antibiotic compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4877561A (en) * 1986-04-02 1989-10-31 Takeda Chemical Industries, Ltd. Method of producing liposome
WO2001054693A1 (en) * 2000-01-31 2001-08-02 Eisai Co., Ltd. Use of thiostrepton as an anti-mycobacterial agent
WO2008127746A1 (en) * 2007-01-10 2008-10-23 Board Of Regents The University Of Texas System Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Discovery of a Biologically Active Thiostrepton Fragment;K. C. Nicolaou et al;《J. AM. CHEM. SOC》;20050610;第127卷;第15042-15044页，尤其是第10542页右栏最后1段 *
G.. Chimote,et al.Evaluation of antitubercular drug-loaded surfactants as inhalable drug-delivery systems for pulmonary tuberculosis.《Journal of Biomedical Materials Research Part A》.2008,第281-292页,尤其是摘要,第282页左栏第2段、最后1段. *

Also Published As

Publication number Publication date
US8697653B2 (en) 2014-04-15
TW201208716A (en) 2012-03-01
RU2013109384A (ru) 2014-09-10
WO2012017405A1 (en) 2012-02-09
AU2011287205A1 (en) 2013-03-07
US20130125879A1 (en) 2013-05-23
MX2013001325A (es) 2013-10-28
ZA201301662B (en) 2014-08-27
KR20130109106A (ko) 2013-10-07
JP2013532722A (ja) 2013-08-19
CA2807357A1 (en) 2012-02-09
IN2013MN00329A (cg-RX-API-DMAC7.html) 2015-05-29
BR112013002641A2 (pt) 2016-06-07
EP2600842A1 (en) 2013-06-12
CN103442694A (zh) 2013-12-11

Similar Documents

Publication Publication Date Title
Yu et al. Inhalable liposomal powder formulations for co-delivery of synergistic ciprofloxacin and colistin against multi-drug resistant gram-negative lung infections
US11883460B2 (en) Antibiotic compositions for treating bacterial infections
Sharma et al. Dynamic mucus penetrating microspheres for efficient pulmonary delivery and enhanced efficacy of host defence peptide (HDP) in experimental tuberculosis
US9861616B2 (en) Methods for treating respiratory diseases and formulations therefor
Pilcer et al. Carrier-free combination for dry powder inhalation of antibiotics in the treatment of lung infections in cystic fibrosis
CN101287446A (zh) 抗生素制剂、单位剂量、试剂盒以及方法
CN101222927A (zh) 气溶胶化的氟喹诺酮类药物及其应用
CA2275502A1 (en) Methods and compositions for improved bioavailability of bioactive agents for mucosal delivery
CN103717231A (zh) 干粉万古霉素组合物以及相关方法
JP2011513258A (ja) 改善された不純物プロファイル及び安全性を有し、吸入により投与される抗真菌薬を有するナノ懸濁液
WO2015107482A1 (en) Pharmaceutical combination for treatment of tuberculosis
JP7165146B2 (ja) グリコペプチド誘導体化合物およびそれらの使用
CN103442694B (zh) 治疗感染性疾病的肺部给药的抗感染分子微粒制剂
Douafer et al. Characterization of a new aerosol antibiotic/adjuvant combination for the treatment of P. aeruginosa lung infections
Saha et al. Repurposing ebselen as an inhalable dry powder to treat respiratory tract infections
TWI713972B (zh) 改善呼吸道健康之益生菌株及其組合物與用途
KR20180036958A (ko) 치료 목적을 위해 층판소체를 이용하기 위한 조성물 및 방법
CN100574757C (zh) 乙酰半胱氨酸或其盐和抗感染药物的组合物
EP3883589A1 (en) Lipo-glycopeptide cleavable derivatives and uses thereof
RU2836760C1 (ru) Способ получения липосомальной лекарственной формы ацетилцистеина
CA3062567C (en) Glycopeptide derivative compounds and uses thereof
WO2023171588A1 (ja) 抗菌薬を含有するｐｌｇａ製剤
CN117899020A (zh) 一种载抗生素黏液渗透型脂质体粉雾剂的制备方法及其应用
Gaspar Pulmonary targeting and biopharmaceutical evaluation of levofloxacin administered as innovative microsphere aerosols

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150909

Termination date: 20160804